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Background: Insulin initiation and titration in primary care is necessary to respond to the growing epidemic of
type 2 diabetes (T2D). The INITIATION study aims to evaluate the impact of implementing a new model of care
with Primary Care Physician and Practice Nurse (PN) teams supported by a Credentialed Diabetes
Educator-Registered Nurse (CDE-RN) and endocrinologist in initiating and titrating basal and prandial insulin
for T2D patients in the Australian healthcare system over 24 weeks. This study also explores the feasibility
and efficacy of retrospective continuous glucose monitoring (r-CGM) in comparison with self-monitoring
of blood glucose (SMBG) among people with T2D in primary care.
Methods/Design: The study employs a before and after design with a nested exploratory trial of SMBG and r-CGM.
A total of 102 insulin naïve T2D patients with a glycated haemoglobin (HbA1c) level of >7.5% in the previous
6 months while treated with maximal oral therapy will be recruited and screened from 22 primary care practices in
Melbourne, Australia. All patients will be commenced on a basal insulin regimen following randomization into one
of the two blood glucose monitoring arms, with intensification to a “basal plus” regimen if required. The outcomes
of the new model of care will be benchmarked with data collected over the same period from a specialist setting
in Melbourne, Australia.
Discussion: This article describes the study protocol and insulin treatment algorithm employed in the first study to
explore r-CGM use among T2D in primary care. Findings from the INITIATION study will inform development of a
larger randomized controlled trial.
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There are currently 347 million people with diabetes
world-wide and this number is expected to rise rapidly,
particularly those with type 2 diabetes (T2D) [1]. Uncon-
trolled diabetes results in premature morbidity and mor-
tality and contributes to the burden faced by society and
its health systems [1]. Optimal glycemic control among
people with T2D is essential to reduce the risk of devel-
oping macro and microvascular complications [2]. Yet,
despite available evidence based guidelines for diabetes
management, there is a persistent failure to achieve gly-
cemic targets among almost half of those people diag-
nosed with T2D [3,4].
The role of insulin in the management of T2D is well
established [5]. However, insulin is often initiated too
late in the disease progression of T2D. Data from the
INSTIGATE study conducted in Europe showed that the
average glycated haemoglobin (HbA1c) upon which in-
sulin was initiated was 9.2% [4]. In Australia, the Fre-
mantle Diabetes Study, reported a median HbA1c of
9.4% prior to insulin commencement [6]. Even when in-
sulin is initiated as part of T2D management, the initial
insulin regimen is often not intensified, leaving the aver-
age HbA1c still well out of target, with only 17% of
people commenced on insulin achieving target HbA1c
[7,8]. Given the growing prevalence of T2D and the lim-
ited availability of diabetes specialist resources, insulin
initiation and titration in primary care is necessary for
uncomplicated patients [9,10].
A single daily dose of basal insulin is used in nearly
two thirds of primary care patients with T2D treated
with insulin [4,11]. However the majority of people with
T2D and elevated fasting glucose levels also have post-
prandial hyperglycemia [12]. Over two-thirds of patients
in the 4-T study needed more than one type of insulin to
achieve target HbA1c suggesting that once insulin is ini-
tiated, monitoring and intensification of insulin therapy
is required [13]. The “basal plus” insulin regimen ad-
dresses the meal with the highest post-prandial glucose
levels after fasting glucose levels are at target following
the introduction and up-titration of basal insulin [14].
Assessing post-prandial glycemia is regarded as the
most significant obstacle in the initiation and titration
of rapid-onset, short-acting prandial insulin. Obtaining
high quality post-prandial readings from patients is often
a challenge [15]. Retrospective-continuous glucose mon-
itoring (r-CGM) devices provide more reliable and
detailed glucose recordings post meals. Use of these
devices thus may increase the timeliness and safety of
insulin initiation and up-titration among people with
T2D, particularly by identifying asymptomatic nocturnal
hypoglycemia and unrecognized post-prandial glucose
elevations [16,17]. This technology has been used widely
in type 1 diabetes (T1D) in specialist centers, howeverevidence regarding the utility and efficacy of this tech-
nology in primary care is lacking [18-20]. While atten-
tion needs to be paid to the technical evidence relating
to insulin introduction, addressing barriers to the initi-
ation of insulin and tailoring the interventions at the
levels of patient, health professional and health system
will ensure the interventions are widely acceptable and
sustainable in primary care [21-23].
The primary aim of this study is to evaluate the feasi-
bility and glycemic outcomes resulting from the imple-
mentation of a new model of care in primary care [24]
facilitating the addition of a basal +/− prandial insulin
regimen in T2D patients with inadequate glycemic
control on oral therapy alone. It involves primary care
physician/Practice Nurse (PN) teams with support in a
“hub-and-spoke” fashion from Credentialed Diabetes
Educator – Registered Nurse (CDE-RN) and endocrinol-
ogists. The secondary aim of the study is to evaluate the
performance and clinical impact of r-CGM in guiding
insulin dosing in primary care.
Methods/Design
The INITIATION study incorporates a model of care
with the PN and primary care physician working as a
team to initiate and titrate basal and prandial insulin in
the Australian primary care setting. The new model of
care is evaluated using a before and after study design.
Resources have been developed to guide these primary
care teams to effectively implement the study protocol
(Figure 1). Support and mentorship will be provided to
primary care physicians and PNs by the study CDE-RN
and the study endocrinologist. Nested within this study
is an exploratory trial of two different types of blood glu-
cose monitoring. Participating T2D patients will be ran-
domized to one of two arms, namely the self-monitoring
of blood glucose (SMBG) alone (Freestyle Optium™;
Abbott) or with an adjunct r-CGM (iPro™2/Enlite™;
Medtronic). Each patient will be followed for 24 weeks
post-randomization with outcomes related to measures
of glycemia (identification of elevated post-prandial
glucose levels and the time required to reach target
glycemia), quality of life and utilization of health profes-
sionals’ time spent with patients.
Ethics approval and trial registry
The INITIATION study has been approved by St
Vincent’s Health Human Research Ethics Committee
(HREC D-106/10) and was registered with the Human
Research Ethics Committee at the University of Melbourne
(HREC 1135260) and the Baker-IDI. Consent will be ob-
tained from participating primary care team and pa-
tients. The INITIATION study was registered with the
Australian and New Zealand Clinical Trials Registry
(ACTRN12610000797077).
Self-Monitoring of Blood Glucose (N=51)

































Figure 1 Overview of the INITIATION study protocol.
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Strategies and materials in the INITIATION study, in-
cluding the model of care, recruitment and study proto-
col, are adapted from an acceptability and feasibility
study in five primary care practices in metropolitan
Melbourne [24].
Training in the model of care
All participating primary care physicians and PNs will
receive a 2-hour education and training session led by
the study endocrinologist, primary care physician and/or
CDE-RN. The focus of the training will be on establish-
ing a collaborative model of care which includes:
 The primary care physician-PN team working in
partnership to identify and support the initiation of
insulin in appropriate patients.
 An in-practice system to initiate and titrate insulin
(e.g. detailed description of the roles of the team
members and within-practice systems of referral and
communication between primary care physician and
PN).Table 1 Insulin titration algorithm
Fasting BGL (mmol/L)* Glargine titration
<4.0 Reduce by 2–4 units
4.0-7.0 No change
7.1-8.0 Add 2 units
8.1-10.0 Add 4 units
>10.0 Add 6 units
BGL = Blood Glucose Level.
#Upon GP’s discretion.
*For values in mg/dl multiply by 18. Simple protocols and insulin titration algorithms.
 Study endocrinologist and CDE-RN support as
appropriate and necessary.
The training of the primary care physician and PN
teams will be interactive and hands-on, using case stud-
ies and delivered either in-practice or during an evening
group session. The session will cover evidence and ra-
tionale for insulin use, how to motivate patients and deal
with common patient-level barriers to insulin initiation,
initiating and titrating basal insulin (glargine; Sanofi)
and prandial insulin (glulisine; Sanofi) using a structured
protocol (Table 1 and Figure 2A and 2B). The same type
of disposable injecting device (Solostar™, Sanofi) will be
used for both insulin glargine and glulisine. The training
will involve demonstration of these insulin devices and
the r-CGM device (iPro™2/Enlite™; Medtronic).
The aim of the training is to ensure that the primary
care physician/PN teams have the knowledge, systems,
supports and confidence to work collaboratively with
participating patients to commence insulin. Importantly,
referral or consultation with an endocrinologist, CDE-2 hr post prandial BGL (mmol/L)* Glulisine titration
<4.5 Reduce by 2–4 units
4.5-7.0 No change
7.1-10.0 Add 0–2 units#
10.1-12.0 Add 2 units
12.1-14.0 Add 4–6 units
> 14.0 Add 6–8 units#
A
Are they in target range (4.0-7.0mmol/L)? If yes, leave dose unchanged
Are they high (>7.0mmol/L)? If yes, increase dose by 2 Units if averaging 7-8mmol/L; 
by 4 Units if averaging 8-10mmol/L; or by 6 Units if averaging >10mmol/L
Are they low (<4.0mmol/L)? If yes, reduce dose by 2-4 Units
# Each colour line represents one day of retrospective glucose monitoring tracing. The
green bar represents target glycemic area. Glucose measurement of interest is circled in 
red.
X axis represents time (a=am; p=pm).
Y axis represents blood glucose level in mmol/L.
 B
Are they all in target range (4.5-10mmol/L)? If yes, no action needed
Are any high (>10mmol/L)? If yes, increase dose by 2 Units if averaging 10-12mmol/L; 







Are any low (<4.5mmol/L)? If yes, reduce dose by 2-4 units
## Each colour line represents one day of retrospective glucose monitoring tracing. The 
orange, green and blue bars represents target glycemic area. Glucose measurement of 
interest is circled in red.
X axis represents meal time in hours.
Y axis represents blood glucose level in mmol/L.
Figure 2 Glargine and glulisine titration schedule based on r-CGM traces. A Glargine titration schedule based on r-CGM traces using the
average glucose levels overnight#. B. Glulisine titration schedule based on r-CGM traces using the glucose levels following meals##.
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main as management options for primary care physi-
cians managing study patients.Intervention with participating patients
A scheduled visits manual has been developed to guide pri-
mary care physicians and PNs to follow-up participating
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to implement the study protocol in a real-world primary
care setting.
The baseline assessments and enrollment visits with
the primary care physician and PN will be arranged for
each participating patient by practice staff. At this visit
the PN will lead the discussion with the patient around
general diabetes management and education and train
patients to administer a single injection of insulin glar-
gine with the Solostar™ injecting device. PNs will then
review patients on Day 2 using a checklist and will
supervise patients administering the second injection
of insulin glargine themselves. While patients will be ad-
vised to administer glargine at the same time daily, they
can choose the most appropriate time that will fit in
with their daily activities.
The primary care teams will be provided with a simple
dosing protocol (see Table 1 and Figure 2) to initiate
and titrate insulin with options to deviate from this
protocol according to their clinical judgment. The
protocol is to target fasting glucose level with once daily
insulin glargine starting from 10 units, although this
can be modified at the discretion of the physicians. Oral
hypoglycemic agents will remain unchanged at the time
of basal insulin initiation in order to ensure that gly-

















































































































































































































































Figure 3 Overview of monitoring schedule.of the insulin in a group of patients with glycemic
control that is already suboptimal. The subsequent titra-
tion visits will occur according to a structured schedule
(Figure 3). An assessment for the need for prandial insu-
lin can occur at any time four weeks post initiation of
basal insulin. After the fasting glucose level target is
reached, the primary care teams will be instructed
to target the highest post-prandial rise with a pre-meal
insulin glulisine injection starting from 4 units with
titration guidelines provided (Table 1). Again the subse-
quent titration visits will occur according to a struc-
tured schedule (Figure 3).
The initial dose and titration schedule for insulin glar-
gine (Table 1) is modified from the AT.LANTUS study
[25]. The initial dose of insulin glulisine is based on the
INITIATE study while the titration schedule (Table 1) is
adapted from the study by Janka et al. [26,27]. Titration
algorithms for the two monitoring arms (SMBG and
r-CGM) are designed so as to provide equivalent incre-
ments in insulin in response to measured glucose read-
ings. They are also designed to minimize the risk of
hypoglycemia. The study CDE-RNs and endocrinologist
will continue to provide support and mentoring to pri-
mary care physicians and PNs during insulin initiation
and titration as required and will perform safety moni-
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Inclusion criteria and recruitment strategies for primary
care practices
Inclusion criteria for primary care practices include:
 The primary care practice employs a PN;
 Primary care physicians and PNs have not
previously routinely initiated insulin in their
practice.
A list of potential practices in the state of Victoria,
Australia will be identified from the primary care prac-
tice database at the University of Melbourne and referral
network of the study investigators (St Vincent’s Hospital,
Werribee Mercy Hospital and Baker-IDI Heart and Dia-
betes Institute). Recruitment will commence within
metropolitan Melbourne. An invitation letter and a
study flyer will be mailed to eligible practices. Primary
care physicians from eligible practices will be contacted
by one of the study investigators. Practices who express
an interest in participating will receive an in-practice
briefing visit by one of the study team. The purpose of
the briefing visit is to explain the study in more detail
and to obtain written consent from the primary care
physicians and PNs to participate in the study.
Inclusion criteria and recruitment strategies for patients
Each consented practice will undertake an audit to identify
potential patients with the most recent HbA1c > 7.5% in
the last 6 months from their electronic medical records
and/or pathology providers. Patients who meet the inclu-
sion and exclusion criteria will be sent a letter by their pri-
mary care physicians recalling them for review of their
diabetes control. During this review, the need for insulin
as one of the treatment options available will be discussed
with the patient. Patients will be provided with written
study information and will be asked to attend a screening
visit with the PN to confirm eligibility to participate.
Each potential patient will be screened by the PN
according to the study inclusion criteria:
 Uncomplicated, insulin naïve T2D patients.
 Aged 18–80 years old.
 On maximum tolerated doses which have been
stable for at least 3 months of two or more oral
hypoglycemic agents (OHAs) or in the opinion of
the physician insulin is deemed necessary.
 Willing to self-monitor blood glucose levels at least
twice daily.
 Willing to commence insulin.
The study exclusion criteria are:
 Patients with T1D. Having satisfactory fasting glucose levels (mean
<6.0 mmol/L) with post-prandial hyperglycemia
(mean >10 mmol/L).
 Having previous or current treatment with insulin
(excluding the short term use of insulin in acute
illness or during hospitalization).
 On Glucagon-like peptide-1(GLP-1) medication
 Non-English speaking.
 Having vision/cognition/renal function impairment
or having major medical/psychiatric illness.
 Having recent or ongoing life-threatening illness.
 Having needle phobia.
 Pregnant or planning to be pregnant.
Screening and baseline assessment
At the screening visit and after written consent is ob-
tained, patients will be provided with and will be taught
to use the study blood glucose meter which will be pro-
vided as well as general diabetes education including
foods containing carbohydrates, the importance of regu-
lar exercise, brief explanation of progression of T2D and
why insulin is now needed, and a blood glucose moni-
toring record book. Patients will be asked to perform
twice daily glucose levels prior to the next appointment.
An r-CGM device will be attached to all patients during
this visit allowing collection of a week’s r-CGM trace
prior to randomization. Patients will then have blood
drawn for HbA1c at the local Diabetes Control and
Complications Trial (DCCT) aligned pathology provider
designated for the study.
Within a week of screening, patients will visit their
primary care team for a baseline assessment and enroll-
ment visit. Those with a study HbA1c ≤7.5% will be ex-
cluded from the study and will be referred back to usual
care. Patients who meet the inclusion and exclusion cri-
teria will be enrolled into the study and will be asked to
complete baseline surveys prior to randomization to ei-
ther self monitoring of blood glucose (SMBG) alone
(Freestyle Optium™; Abbott) or with adjunct r-CGM
(iPro™2/Enlite™; Medtronic). Randomization will be gen-
erated using computerized random number table that
will be held by a researcher independent of the study
team. Random allocation will be kept in sealed envelopes
and randomization will occur prior to the initiation of
insulin therapy. Blinding of researchers, practices and
patients will not be possible once the random allocation
is revealed due to the nature of the study.
Self-monitoring arms
 Self-monitoring of blood glucose with adjunct
(r-CGM) arm
iPro™2/Enlite™; Medtronic is a r-CGM utilising a
subcutaneous electrode measuring and recording
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methodology and requiring twice daily calibration
with a fingerprick glucose meter reading. Minimal
interaction by the patient is required with these
devices which are uploaded to a computer.
Calibrating fingerprick glucose readings are
automatically integrated and an r-CGM trace
facilitated by the device software plotted. Health
professionals will upload data from the r-CGM
device and the blood glucose meter (BGM) at the
end of monitoring period and the retrospective
continuous glucose trace plot will be produced by
the device software. The 7-day r-CGM traces will be
collected weekly for 4 weeks following the initiation
of insulin glargine or glulisine, fortnightly for
another 4 weeks and monthly until the end of the
study.
 Self-monitoring of blood glucose (SMBG) arm
For patients randomized to the conventional SMBG
arm, r-CGM traces will be obtained at baseline,
12 weeks and 24 weeks. Health professionals will be
instructed not to use upload of these r-CGM traces
for titration.
Data collection
At baseline, demographic data, clinical history (year of
diagnosis, complications, medications, frequency of self-
monitoring, hospitalization and hypoglycemia in the past
3 months), smoking status, clinical examination (body
mass index, waist-to-hip ratio, blood pressure), Short
Form 36 Health Survey questionnaire version 2 (SF-36 v2)
[28] and Audit of Diabetes Dependent Quality of Life
(ADDQoL) [29] will be collected. The same data will also
be collected at 12 weeks and 24 weeks. The doses of basal
and prandial insulin administered during study follow-up
will be recorded. Data will be collected in clinical record
forms (CRFs) that are designed to be user-friendly and
easy to administer by busy health professionals working in
a complex clinical environment. The CRFs will be faxed
from primary care centers to a central electronic database
management service.
Each patient will be asked to perform fingerprick ca-
pillary blood glucose testing 2 to 4 times daily including
one fasting reading before breakfast and another reading
at 2 hours after a meal at various times. Patients will be
advised to document these readings and any symptom-
atic hypoglycemic episodes in the blood glucose diary
provided. The glucose meter data will be uploaded at
each practice visit.
Blood collection and assays
HbA1c will be collected at baseline, 12 weeks and
24 weeks and analyzed by a DCCT aligned centralized
laboratory.Follow-up and endpoint determination procedures
The primary endpoint is the absolute change in HbA1c
following insulin initiation at baseline compared with
24 weeks. The secondary endpoints include changes
r-CGM time spent in low (<4.0 mmol/L), target (4.0-
10.0 mmol/L) and high (>10.0 mmol/L) glucose range at
baseline, 12 and 24 weeks; symptomatic hypoglycemia;
incidence of severe hypoglycemia (hypoglycemia result-
ing in loss of consciousness or requiring third party
assistance); proportion of patients being prescribed a
prandial insulin (glulisine) injection; time to reach tar-
get HbA1c ≤7%; proportion of patients achieving an
HbA1c ≤7% at 12 and 24 weeks); total insulin dose at
12 weeks and 24 weeks; change in quality of life
(ADDQOL and SF-36v2 at 12 weeks and 24 weeks com-
pared with baseline); blood pressure (12 weeks and
24 weeks compared with baseline) and weight change
(BMI and waist-to-hip ratio at 12 weeks and 24 weeks
compared with baseline).
Endpoints for the sub-study comparing r-CGM with
SMBG reflect those described above. In addition, pa-
tients and PNs’ acceptability and utility of CGM devices
at 24 weeks and total primary health care utilization at
24 weeks will be examined.Benchmark data
The glycemic outcomes reflected by changes in HbA1c
following implementation of this new model of care in
primary care setting will be benchmarked against obser-
vational data collected from all patients with T2D com-
menced on insulin by private endocrinologists/CDE-RN
teams over the same period. Data to be collected from
benchmark patients at baseline, 12 weeks and 24 weeks
include age, duration of diabetes, the presence of dia-
betic complications (laser requiring retinopathy, ische-
mic heart disease, lower limb ulceration or amputation,
stroke), the frequency of home blood glucose monitor-
ing, the need for an interpreter, employment status,
whether they live alone, hospitalization within the last
12 weeks, current medications and HbA1c. These char-
acteristics will allow a comparison of the demographic,
costs and outcomes of those patients with T2D com-
mencing insulin in the specialist centers with those in
primary care.Sample size calculation
The power calculation was based on one sample com-
parison of mean against a reference value. The HbA1c
reference value was 8.23% as reported in the INSTI-
GATE study [4] assuming no change in HbA1c without
the intervention. The new model of care was estimated
to result in HbA1c reduction of 0.4%. Based on a stand-
ard deviation of 1.44 in the FIELD study [30] with a
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102 patients is required to detect change in the primary
outcome. Our previous research suggests that in an aver-
age two full-time-equivalent primary care physician
practice we expect to identify 80–100 patients with T2D.
Of these we anticipate 10% (8–10) will meet our inclu-
sion criteria and 50% recruitment rate, generating on
average 4–5 participating patients per practice. A total
of 22 primary care practices will be required. Our sam-
ple is not powered to detect change between SMBG and
r-CGM but rather to explore the feasibility and efficacy
of r-CGM in primary care.
Statistical analysis
The primary analysis will be the change in HbA1c based
on the entire sample at baseline, 12 and 24 weeks. This
analysis will produce a conservative estimate of the
benefit of insulin therapy as glycemic control tends to
rise without the introduction of insulin in this popula-
tion. The changes in HbA1c will be benchmarked
against those obtained from patients under specialist
care who have been initiated on insulin. A secondary
analysis will examine the absolute change in HbA1c be-
tween the r-CGM and SMBG groups. Comparisons of
the entire sample as well as between r-CGM and SMBG
will be made at baseline, 12 and 24 weeks for all second-
ary endpoints.
Trial monitoring
A safety monitoring committee consisting of study
endocrinologist, primary care physician and CDE-RNs
will be appointed. All significant adverse events (which
include hospital presentations or admissions) and their
duration will be documented. All serious adverse events
will be reported to the safety monitoring committee
within 24 hours of the primary care team being made
aware of them. Each adverse event will be independently
reviewed by other chief investigators (consisting of 4 en-
docrinologists) independent of the safety monitoring
team. Additionally, the Human Research Ethics Commit-
tee will be notified of all significant adverse events in
writing. Criteria for withdrawal of study participants
include major protocol violation, major adverse event
directly related to the intervention, pregnancy, volun-
tary withdrawal of consent or development of life-
threatening illness.
Discussion
Delays in the timely initiation of insulin are often at-
tributed to “psychological insulin resistance” [31] on
the part of patients and “clinical inertia” on the part of
health professionals. However, barriers associated with
the health system responsible for the provision of med-
ical services are also important. The model of careunder evaluation in this study attempts to address bar-
riers which may be responsible for delaying insulin ini-
tiation in primary care while also utilizing those
strengths inherent in the primary care model. Our pre-
vious work [21] has identified that the organization
within the practice, clarification of the roles and expec-
tations of patient and health professionals involved in
insulin initiation and delegation of responsibility for the
provision of care are key factors in determining success.
Our study introduces a new model of care in Australia,
with an enhanced role for the PNs working in partner-
ship with the primary care physicians, supported by
CDE-RNs and endocrinologists. This model addresses
the barriers and enablers of insulin initiation in the pri-
mary care setting at the practice, health professional
and patient level. It also utilizes the current healthcare
system and financial structures in Australia ensuring
immediate generalizability.
To maximize acceptance in a busy and varied clinical
environment, the tools designed to implement the inter-
vention are flexible with a facility to be tailored to each
practice’s structure and the individual needs of patients.
The insulin initiation and titration protocol employs a
simple unambiguous easy-to-follow algorithm guiding
primary care physicians and PNs in a busy general prac-
tice setting. A basal insulin analogue is employed as it
would minimize the risk of hypoglycemia. This precau-
tion is crucial in order to ensure that the physician’s,
PN’s and patient’s trust in the ability of the model of
care to deliver a positive outcome is maintained. Insu-
lin glargine is chosen because it is the only available
basal insulin that is subsidized by the Pharmaceutical
Benefits Scheme (PBS) for the management of T2D
in Australia at the time this study is conducted. A
basal plus approach, incorporating the rapid acting
analogue, insulin glulisine, acknowledges the import-
ance of addressing post-prandial hyperglycemia in re-
ducing HbA1c in this patient group [32,33]. A similar
disposable injecting device (Solostar™, Sanofi) mechan-
ism used for both glargine and glulisine minimizes
need for further education of primary care physicians,
PNs and patients.
The insulin titration schedule is conservative, balan-
cing sophistication against practicability. Its aim is to
minimize hypoglycemia risk, and has been developed
based upon the review of available research evidence
[14] and clinical experience. Each physician-PN team
will be able to deviate from the insulin initiation and
titration protocol at their discretion. This should
minimize patient adverse events and ensure that it is
feasible for both PNs and physicians to implement this
model of care within their current workload in real-
world practice. Our aim is to embed and integrate the
task of initiating and titrating insulin within the complex
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disruption to work in general.The use of blood glucose monitoring among T2D in
primary care
Once insulin has been initiated, the ongoing monitoring
and review of glucose levels by the patient and health
professional is important for patient safety and for in-
tensification of insulin therapy [13] as this provides
insight into recurring patterns of glycemia, the impact of
diet and behavior upon glycemia and the effect of thera-
peutic interventions [34]. However hypoglycemia may be
undetected particularly when it occurs overnight [35]
and identifying post-prandial glycemia may be a chal-
lenge for clinicians.
The use of r-CGM offers the potential for identifica-
tion of unrecognized hypoglycemia and hyperglycemia
excursions [36] leading to more tailored and appropriate
treatment changes. We chose the iPro™2 r-CGM device
as it is small, convenient and non-intrusive for the pa-
tient to wear and is essentially “wear and forget”. It re-
quires a minimum of two blood glucose meter readings
each day for calibration. The study protocol will result
in the first widespread use of these devices in a “real
world” primary care setting where people with T2D re-
ceive the majority of their health care. Given the ex-
ploratory nature of the r-CGM arm of the study the
design incorporated an intensive r-CGM regimen pro-
viding a level of redundancy sufficient to allow for po-
tential device failures.Study design issues
We have undertaken a series of studies of insulin initi-
ation in primary care based on the UK Medical Research
Council (MRC) complex intervention framework [37]. In
the pre-clinical phase, we examined barriers and en-
ablers of insulin initiation using qualitative approach
[21] drawing upon the Normalization Process Theory
[38]. We then developed and piloted our new model of
care on insulin initiation in five general practices in
Melbourne, Australia as part of Phase 1 modeling stage
of the MRC framework [39]. Our new model of care is
complex as it is made of several interconnecting factors
[40] and it is embedded within the ‘real world’ general
practice setting. In the INITIATION study, we will pro-
gress to a Phase 2 exploratory trial to further refine our
intervention and processes as well as to determine the
feasibility of our study protocol in a much larger sample
of 22 general practices. The exploratory trial stage is
considered important to inform a future definitive ran-
domized controlled trial.
Our study is based in primary care involving “research
naive” practices. Data collection forms and titrationalgorithms need to be easily understood and not time
consuming to complete and follow as the practices will
receive limited reimbursement for their participation in
research. The primary aim of implementing the new
model of care is not only to achieve insulin initiation but
also the treatment intensification required to achieve ap-
propriate glycemic control in a safe manner. The num-
ber of people who transition to prandial insulin and
timeliness with which that occurs is therefore also of im-
portance and this is reflected in the study’s secondary
endpoints. Other secondary endpoints include indicators
clinically relevant to health professionals and patients
when commencing insulin, including quality of life and
weight gain.
Our primary care practices will be a convenience sam-
ple of practices in the state of Victoria and thus will not
be representative of all Australian primary care practices.
A convenience sample is within the scope of this before
and after study with a nested exploratory trial to exam-
ine the impact of our new model of care and observe the
feasibility of r-CGM use among T2D in primary care.
Data relating to insulin initiation from a specialist set-
ting in the same locality as that from which the practices
will be recruited will be used to benchmark study out-
comes. This is incorporated into the study design as
assigning patients with suboptimal glycemic control
judged by their primary care physicians as requiring in-
sulin on clinical grounds to a control “no insulin” group
is not ethically justifiable. Insulin initiation and titration
in the specialist setting is accepted as the “gold standard”
care and the benchmarking data will enable us to com-
pare how our new primary care based model of care per-
formed in improving HbA1c at 12 and 24 weeks. The
benchmarking data will be the basis for a health eco-
nomics analysis comparing the costs of insulin initiation
in the primary care setting versus that in the specialists
setting. A centralised laboratory for HbA1c testing will
be used in this study to ensure that our study HbA1c re-
sult is consistent across participating primary care
practices.
Cluster randomization of monitoring arms according to
the primary care centres recruited for the study would have
been appropriate had we planned a definitive effectiveness
trial powered to identify difference in the change in
HbA1c. Given that the study is not powered to do so, our
individually randomized exploratory design will allow all
practitioners to gain some experience and exposure to the
use of r-CGM, thus maximizing our capacity to identify
strengths and weaknesses in its use in the field.
Conclusions
Insulin initiation in primary care is warranted in
order to address the growing epidemic of T2D. The
INITIATION study evaluates the efficacy of a new
Blackberry et al. BMC Family Practice 2014, 15:82 Page 10 of 11
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dresses barriers to insulin initiation within real-world
primary care setting. The study will be the first to pro-
vide valuable efficacy and utility data on the use of r-
CGM among people with T2D in primary care.
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